KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.98

Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial.

Huabin Hu, Jianwei Zhang, Yunfeng Li, Xiaozhong Wang, Ziqiang Wang, Hui Wang, Liang Kang, Ping Liu, Ping Lan, Xiaojian Wu, Yunhuan Zhen, Haiping Pei, Zhongcheng Huang, Hao Zhang, Wenbin Chen, Yongming Zeng, Jiajun Lai, Hongbo Wei, Xuefeng Huang, Jiansi Chen, Jigui Chen, Kaixiong Tao, Qingwen Xu, Xiang Peng, Junlin Liang, Guanfu Cai, Kefeng Ding, Zhijie Ding, Ming Hu, Wei Zhang, Bo Tang, Chuyuan Hong, Jie Cao, Zonghai Huang, Wuteng Cao, Fangqian Li, Xinhua Wang, Chao Wang, Yan Huang, Yandong Zhao, Yue Cai, Jiayu Ling, Xiaoyu Xie, Zehua Wu, Lishuo Shi, Li Ling, Hao Liu, Jianping Wang, Meijin Huang, Yanhong Deng, OPTICAL study group

J Clin Oncol 42(25) 2978-2988

PMID38564700
PMCID-
DOI10.1200/JCO.23.01889
发表日期2024-04-02
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
摘要

摘要

PURPOSE: The role of neoadjuvant chemotherapy (NAC) in colon cancer remains unclear. This trial investigated whether 3 months of modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or capecitabine and oxaliplatin (CAPOX) as NAC could improve outcomes in patients with locally advanced colon cancer versus upfront surgery. PATIENTS AND METHODS: OPTICAL was a randomized, phase III trial in patients with clinically staged locally advanced colon cancer (T3 with extramural spread into the mesocolic fat ≥5 mm or T4). Patients were randomly assigned 1:1 to receive six preoperative cycles of mFOLFOX6 or four cycles of CAPOX, followed by surgery and adjuvant chemotherapy (NAC group), or immediate surgery and the physician's choice of adjuvant chemotherapy (upfront surgery group). The primary end point was 3-year disease-free survival (DFS) assessed in the modified intention-to-treat (mITT) population. RESULTS: Between January 2016 and April 2021, of the 752 patients enrolled, 744 patients were included in the mITT analysis (371 in the NAC group; 373 in the upfront surgery group). At a median follow-up of 48.0 months (IQR, 46.0-50.1), 3-year DFS rates were 82.1% in the NAC group and 77.5% in the upfront surgery group (stratified hazard ratio [HR], 0.74 [95% CI, 0.54 to 1.03]). The R0 resection was achieved in 98% of patients who underwent surgery in both groups. Compared with upfront surgery, NAC resulted in a 7% pathologic complete response rate (pCR), significantly lower rates of advanced tumor staging (pT3-4: 77% v 94%), lymph node metastasis (pN1-2: 31% v 46%), and potentially improved overall survival (stratified HR, 0.44 [95% CI, 0.25 to 0.77]). CONCLUSION: NAC with mFOLFOX6 or CAPOX did not show a significant DFS benefit. However, this neoadjuvant approach was safe, resulted in substantial pathologic downstaging, and appears to be a viable therapeutic option for locally advanced colon cancer.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。